Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes. Insulin-dependent diabetic patients have a large exchangeable body sodium pooi, secondary to sodium retention. The pathogenesis of impaired natriuresis in insulin dependent diabetes remains to be elucidated. The present study examines the role of hyperinsulinemia, impaired atrial natriuretic release, and resistance to atrial natriuretic peptide action in determining sodium retention in normotensive and hypertensive insulin-dependent diabetic patients.
plasma insulin 48 4 , P < 0.01). Seven control subjects had lower extracellular liquid volume than eight insulin-dependent diabetic patients (11.0 0.8 1/1.73 m2 vs. 14.8 0.9, P < 0.05) and also had baseline plasma atrial natriuretic peptide concentrations (18 5 pg/mI vs. 37 4, P < 0.05). Atrial natriuretic peptide response to saline challenge was blunted in insulin-dependent diabetic patients when saline was administered on the basis of body surface area (90 nimol/l.73 m2 . 90 mm) but not when administered on the basis of extracellular liquid volume (ECV) (8.2 mmol/liter ECV 90 mm). Continuous infusion of atrial natriuretic peptide in the same control and diabetic subjects (0.06 rg/kg mm . 120 mm) resulted in similar circulating concentrations of the hormone but in significantly lower sodium excretion rate in diabetic (from 185 19 to 193 21 smol/f .73 m2 mm) than in control subjects (199 14 to 341 22, P < 0.01). Natriuretic action of atrial natriuretic peptide was similarly impaired in a group of eighteen hypertensive insulin-dependent diabetic patients in comparison with a matched group of seven hypertensive control patients. Angiotensin converting enzyme inhibitor treatment in these hypertensive diabetic patients decreased extracellular liquid volume and improved natriuretic response to atrial natnuretic peptide. We conclude that refractoriness to natriuretic action rather than impaired release of atrial natriuretic peptide can further deteriorate sodium retention in insulin dependent diabetes. This altered hormonal behavior could be primarily due to insulin-induced sodium retention and extracellular liquid volume expansion.
A large exchangeable body sodium pool has been reported in normotensive [1] [2] [3] and hypertensive [4] IDDM patients who are without evidence of renal or vascular complications. Ex-© 1992 by the International Society of Nephrology changeable body sodium pool is further increased in IDDM patients with established nephropathy (defined as albumin excretion of greater than 500 mg/24 hr) [5] and also in those with microalbuminuria or incipient nephropathy (defined as albumin excretion rate between 30 and 500 mg/24 hr) [6] .
The increased exchangeable mass of sodium is accompanied by a concomitant increase in the ECV [6, 7] and of plasma volume [81, although this latter finding has not been uniformly confirmed [4, 6] . An expansion in sodium exchangeable mass has been frequently advocated to explain the frequent association between hypertension and IDDM [9] . However, it has to be pointed out that some studies have also reported that the prevalence of hypertension in IDDM is similar to that showed by a non-diabetic population [10] . From a hemodynamic point of view, a larger plasma volume and an expanded ECV could lead to increased cardiac output and in turn to increased blood pressure levels and glomerular filtration rate. This cascade of events should be eventually able to buffer the expansion in the magnitude of ECV [11, 121. According to this hypothesis, the expansion in plasma volume is an early and transient phenomenon which is rapidly overcome by the cardiovascular feedback system to maintain a stable hemodynamic condition in all tissues [11, 12] , and it is therefore missed if plasma volume is evaluated when this hemodynamic rearrangement has already occurred. Whatever the relationship between plasma and ECV, IDDM patients have impaired natriuretic response to volume expansion either induced by head-out water immersion [5, 13, 14] or by saline infusion [3] . The pathogenesis of this impaired capacity of handling a sodium load in IDDM is unclear. The present study examines the role of insulin and ANP in determining sodium retention in IDDM.
Methods

Patients
Twenty-six type I, insulin-dependent diabetic (IDDM) patients with onset of the disease before the age of 30, aged 17 to 42 years, were divided into two groups: normotensives (N = 8) with blood pressure levels below 140 and 85 mm Hg and hypertensives (N 18) with blood pressure levels above 145 and 90 mm Hg, for systolic and diastolic values, respectively, according to the statement on Hypertension in Diabetes Mellitus [15] . Seven non-diabetic hypertensive patients and seven normotensive healthy subjects were selected from those attending the outpatient clinic of the Internal Medicine Department, University of Padova. A complete medical workup was performed to rule out the diagnosis of secondary hypertension. Kidney, liver and endocrine (except for IDDM) function was normal. An additional criterion for inclusion in the study was the presence of normal body weight (<15% above or below desirable body weight) [163. IDDM patients with duration of diabetes higher than 11 years were not included. Patients with neovascularization and fibroproliferation on standard eye examination, or with autonomic neuropathy, were also not taken into consideration. All IDDM patients were taking two or three daily subcutaneous insulin injections. Only patients who showed HbAIC values lower than 7.5% in the 12 months preceding the study were included. In the six months preceding the study, each patient was visited at least twice a month by one of the physicians involved in the study. Major efforts were dedicated to improve the degree of metabolic control. Each patient was admitted to the hospital one week before the study. Eight out of the eighteen hypertensive IDDM patients were on antihypertensive therapy: five on beta-blockers, two on calcium antagonists and one on angiotensin converting enzyme inhibitors. Hypertensive IDDM patients on antihypertensive treatment had sodium excretion rates not significantly different from those of patients who were without previous treatment during the week of admission in the ward. Any antihypertensive therapy was discontinued one week before hospital admission and during hospital stay, and subjects followed an isocaloric diet containing 50% carbohydrate, 25% fat, and 25% protein.
The daily intake of NaCl was 100 mmol/day during the week preceding each study. All control and IDDM subjects were considered to be in sodium balance in the three days preceding each study on the basis of sodium intake and sodium excretion rate values. The estimated sodium intake before hospital admission was 100 to 150 mmol/day without significant differences between control and IDDM subjects. Plasma ct-eatinine concentration was normal in all IDDM and control subjects. All subjects and patients had sterile urine and normal urine microscopy. The level of albumin excretion rate was determined as the median value of three 24-hour urine collections, free of ketone bodies within a fortnight. Control subjects and norniotensive diabetic patients had an albumin excretion rate lower than 20 g/min; 6 out of the 18 hypertensive diabetic patients had an albumin excretion rate higher than 20 g/min and lower than 36 g/min (Table 1 ). All subjects gave informed consent and the experimental design was approved by the local Ethical Committee of the University of Padova.
Procedures
Study 1: Effects of hyperinsulineinia. Normotensive IDDM patients were studied thrice: A) during conventional insulin regimen, with two daily injections of soluble (Actrapid HM, Novo, Rome, Italy) and long acting (Protophane HM, Novo) insulin preparations before breakfast and dinner (0.5 U/kg/day); B) during intensified insulin regimen with three daily injections of soluble insulin before breakfast, lunch and snack, and with one evening injection of soluble and long-acting insulin preparation before dinner (0.7 U/kg/day); C) during intensified insulin Abbreviations are: S, systolic; D, diastolic.
regimen as described in (B), but with variable amounts of glucose infusion in order to clamp blood glucose concentrations at hyperglycemic levels (between 10 and 20 mmol/liter), using a Beckman glucose analyzer to determine blood glucose concentration with a glucose-oxidase technique (Beckman, Milano, Italy) every fifteen minutes, and a Harvard continuous infusion pump (Harvard, Apparatus, Boston, Massachusetts, USA).
Other details have been provided elsewhere [17] . Intermittent blood samples were withdrawn every 60 minutes to measure plasma glucose and free insulin concentrations. Twenty-fourhour urines were collected to determine daily sodium excretion rate. During protocol, an overnight fasting blood sample was taken for measurement of plasma renin and creatinine concentration. Study 2: Atrial natriuretic peptide response to isotonic volume expansion. Normotensive IDDM patients and control subjects received a single intravenous injection of 3.7 MEq 51chromium edetic acid (51Cr EDTA) after an overnight fast at euglycemic levels achieved in IDDM patients by a subcutaneous overnight continuous infusion of insulin (Actrapid HM 15 mU/kg. hr with a bolus MC 20 insulin-infusion device; Miles, Ames, Cavenago, Milan, Italy) in order to measure ECV. Blood samples for tracer determination were drawn before and 1, 2, 3, hormonal parameters and sodium excretion rate were evaluated as described elsewhere [3, [19] [20] [21] .
Study 3: Responsiveness to atrial natriuretic peptide. Renal and systemic responses to atrial natriuretic peptide (ANP) infusion were studied in seven normotensive and seven hypertensive non-diabetic patients, and eight normotensive and eighteen hypertensive diabetic patients. In addition the eighteen hypertensive diabetic patients were also studied in a second occasion after three months of treatment with angiotensin converting enzyme inhibitor (Cilazapril, Ro 31-2848, F. Hoffmann-La Roche Co. Ltd., Basel, Switzerland). All subjects were studied in the morning after an overnight fast in a recumbent position. Intravenous catheters were placed bilaterally for administration of ANP and blood sampling, respectively. Urine samples were obtained by free voiding at timed intervals. After a stabilization period of 30 to 60 minutes following intravenous catheter placement, all individuals received an oral water load of 500 ml. Renal plasma flow and glomerular filtration rate were determined as previously described during Study 2. After completion of the 120-minute equilibration period, there were three 30-minute phases of urine collection at baseline, and four 30-minute phases of urine collection during the ANP constant infusion at a rate of 0.06 tgIkg. mm 120 mm, preceded by a priming dose of 10 and 15 sg ANP bolus intravenous injection in non-diabetic and IDDM subjects, respectively. Urine output was replaced on a milliliter per milliliter basis throughout the study by administering oral water. All infusion were given by a constant-rate infusion pump, with the final concentration of ANP adjusted for patient's body weight. The administered volume during the experimental infusion period was 50 ml/l.73 m2 120 mm. Equal volumes of 0.9% sodium chloride were given during the baseline phase for each individual. Heart rate and cuff blood pressure were recorded at 10 minute intervals, throughout the study. Upon completion of lead-in stabilization and each of the urine collection periods, blood samples were obtained for '251-para-aminohippurate ('251-PAH) and 51Cr-EDTA radioactivity (dpm/ml). Serum electrolytes, hematocrit, serum protein (albumin and total) and plasma inimunoreactive (ir) ANP were obtained upon completion of lead-in stabilization and each of the urine collection periods. Urine collections were obtained at time 0 and at the end of each collection period for volume, ' 251.PAH and 51Cr-EDTA radioactivity (dpm/ml), and sodium. Plasma glucose, insulin, atrial natriuretic peptide, hemoglobin A1, electrolyte and protein concentrations were measured as described in detail elsewhere [3, [19] [20] [21] , as well as glomerular filtration rate, renal plasma flow, sodium excretion and albumin excretion rate [3, [19] [20] [21] . Standard parametric and non-parametric statistical analysis was used to assess the degree of significant differences [3, .
Results
Effects of hyperinsulinemia with euglycemia (Study 1) IDDM patients, during conventional insulin treatment, had a daily mean value of plasma glucose of 11.5 1.3 (mmol/liter) and plasma insulin of 27 3 (jiU/ml). During intensified insulin regimen with strict metabolic control plasma glucose concentration decreased to 6.3 0.8 (mmol/liter; P < 0.01) and plasma insulin concentration rose to 44 4 (U/ml; P < 0.01). During intensified insulin regimen along with hyperglycemic glucose clamp plasma glucose concentration was between 12.5 and 15.0 mmol/Iiter throughout most of the day, whereas plasma insulin concentration was not significantly different from that found during intensified insulin regimen (48 4 tU/m1) with strict metabolic control without additional glucose administration. Daily sodium excretion rate was 147 16 mmol/24 hr during conventional insulin regimen (Fig. IA) and decreased to 91 12 mmol/24 hr (P < 0.01) during intensified insulin regimen with strict metabolic control (Fig. 1B) and to 107 13 mmol/24 hr (P <0.01) during the intensified insulin regimen along with hyperglycemic glucose clamp (Fig. IC) . Daily sodium excretion rate 
÷0
during intensified insulin regimen with strict metabolic control was slightly but significantly lower than that during intensified insulin regimen along with hyperglycemic glucose clamp (Fig. 1 B vs. C, P < 0.05).
ANP response to isotonic volume expansion (Study 2) ECV was larger in IDDM patients (14.8 0.9 1/1.73 m2) than in control subjects (11.0 0.8 1/1.73 m2, P < 0.05). Baseline ANP plasma values were significantly higher in IDDM patients (37 4 pg/mi) than in control subjects (18 5 Responsiveness to ANP (Study 3) ANP administration resulted in similar circulating concentrations of the hormone (291 35 vs. 302 39 pg/mI), but resulted in significantly higher sodium excretion rates in normotensive controls (from 199 14 to 340 22 jsmol/min 1.73 m2, P < 0.01) than in normotensive IDDM patients (from 185 19 to 193 21 mol/min 1.73 m2, NS; Fig. 2 ). ANP raised significantly hematocrit and plasma protein values in normotensive control subjects but not in hypertensive IDDM patients (Fig, 2) . Mean blood pressure fell and glomerular filtration rate was raised both in normotensive control and normotensive IDDM patients, albeit this hormonal action of ANP was more marked in controls than in IDDM patients (Fig. 2) . Filtration fraction (FF) was increased significantly in normotensive IDDM patients but not in normotensive control subjects (Fig. 2) . A resistance to the action of ANP was shown also in hypertensive IDDM patients in comparison with hypertensive control patients with regard to sodium excretion rate, hematocrit, mean blood pressure and glomeruiar filtration rate (Fig. 3) .
Effects of angiorensin converting enzyme (ACE) inhibition in
hypertensive IDDM patients (Study 4) Three months of treatment with Cilazapril, an ACE inhibitor, significantly decreased blood pressure levels, albumin excretion rate, and baseline ANP concentration (Table 2) . No change was found in GFR, whereas RPF was significantly increased. Daily sodium excretion rate increased significantly from 94 14 (mmol/24 hr) to a peak value of 142 18 (mmol/24 hr; P < 0.01) in the first month of ACE inhibitor treatment (Fig. 4) . On average IDDM patients had an overall loss of 679 66 mmoi during the 3 month antihypertensive treatment. Thereafter daily sodium excretion rate went down to the rate shown by hypertensive TDDM patients before ACE therapy (Fig. 4) ON.. tion of these studies is that insulin administration showed an antinatriuretic action, mainly after acute administration with plasma hormone concentrations, higher than those found in normal subjects. Moreover, the subjects who participated in most of these studies followed a diet containing a supplementation of sodium chloride [26, 29] . Little information is available in humans on the sodium retentive effect of insulin after more prolonged administration which results in hormone concentrations closer to physiological levels during diets having a normal sodium intake.
With regard to insulin-dependent diabetes, it has to be pointed out that sodium excretion rate is heavily influenced by the circulating levels of glucose [30] as well as of ketone bodies, lactate and other intermediate compounds [19-21, 31, 32] , which are often altered in diabetic patients with poor metabolic control with low plasma insulin levels. Therefore, to elucidate the role of insulin on sodium retention in IDDM, the sodium excretion rate has to be investigated during hormone administration, resulting in similar insulin circulating concentrations both at hyperglycemic and euglycemic levels.
The present study demonstrates that daily sodium excretion rate is lower in euglycemic and slightly hyperinsulinemic than in hyperglycemic underinsulinized IDDM patients during a diet with normal sodium intake. Hyperinsulinemia itself, irrespective of or in addition to hyperglycemia, seems responsible for the increased transport of sodium from intratubular space to circulation, as the sodium excretion rate was significantly lower in hyperglycemic and hyperinsulinemic diabetic patients, suggesting that hyperglycemia is not capable of counterbalancing the action of insulin in renal sodium handling. Plasma hyperinsulinemia is almost unavoidable during subcutaneous insulin therapy in IDDM, since higher circulating levels of this hormone are needed to achieve and maintain euglycemia for peripheral rather than intraportal insulin administration [17] and for insulin resistance [33] . Hyperinsulinemia, in turn, determines sodium retention and expansion of ECV. A common feature of the syndromes characterized by salt and fluid retention is the development of hormonal abnormalities in the attempt to protect the cardiovascular system from an excessive circulating volume overload [34] . In IDDM, for instance, insulin-induced sodium retention is accompanied by lower renin and aldosterone and by higher angiotensin II and norepinephrine plasma concentration, an endocrine reassessment aiming to raise kidney sodium excretion even by increasing blood pressure levels.
Thus one should predict that sodium retention and an expansion in ECV in IDDM leads to increased cardiac release of ANP [35] . ANP is indeed elevated in a subgroup of patients with essential hypertension who have low renin concentrations, a hormonal behavior resembling that of IDDM patients [36] .
ANP release The present study confirms previous findings of our laboratory [31 that euglycemic well-insulinized IDDM patients have higher baseline plasma concentrations of ANP. The most plausible mechanism accounting for this hormonal abnormality is a chronic stimulation of cardiac release into circulation of ANP, by intra-and extravascular volume expansion secondary to insulin-induced sodium retention. Our results are in keeping with those of the majority [3, 14, [37] [38] [39] [40] , but not all [2, 13, 41] , of the previous reports on this matter. These discrepancies concerning the patterns of ANP in IDDM could be due to the following reasons. First, central blood volume, rather than intravascular volume per Se, is a determinant of ANP release.
Therefore it can be postulated that ANP can be normalized whenever IDDM patients are capable of reassessing a hormonal milieu to keep a constant circulating blood volume, despite insulin-induced extracellular volume expansion. Second, most of the above-cited studies were performed in poorly-controlled IDDM patients, in whom glycosuria could have caused marked sodiuria and dehydration. Trevisan et al [42] recently showed that hyperglycemia can paradoxically ameliorate the abnormalities, both in ANP release and action, shown by IDDM patients at euglycemic levels.
With regard to ANP release in response to different stimuli, we previously found impaired ANP release during salineinduced isotonic volume expansion [3] . On the contrary, normal circulating ANP response has been found after head-out of water immersion in IDDM patients [5, 14] . These findings are only apparently in disagreement, as one has to bear in mind that IDDM patients had larger ECV. Therefore it is likely that head-down-tilt or head-out of water immersion causes a more potent redistribution of intravascular fluid volume from the periphery to the thoracic space in IDDM than in non-diabetic subjects, which in turn results in normal or even higher ANP release. On the contrary, saline infusion is not able to adequately stimulate ANP in IDDM patients, since saline load is excessively diluted in the larger ECV, which leads to impaired distension of atrial myocytes. When saline challenge is administered on the basis of the magnitude of ECV instead of body weight, ANP response to isotonic volume expansion was comparable in IDDM and control subjects. However, the sodium excretion rate was always significantly lower in IDDM than in normal subjects, whatever the infused saline load, even when the release of ANP was comparable in controls and IDDM patients. This latter finding raises the hypothesis that resistance to, rather than impaired release of ANP, plays a pivotal role in determining sodium retention in IDDM.
Resistance to ANP The results of the present study demonstrate that the action of ANP is blunted both in normotensive and in hypertensive IDDM patients at euglycemic levels.
These findings are in agreement with the observation of Jungman et al [43] that in normotensive IDDM patients there is evidence for a decreased responsiveness to ANP with regard to excretion of renal fluids, sodium and chloride. In addition, we found that the hormonal action of ANP on kidney hemodynamics, blood pressure levels and other parameters of fluid retention, such as hematocrit and plasma proteins, was impaired in IDDM in comparison with normal subjects. At variance with the above-cited reports and with our findings, normal effects of ANP on systemic and renal hemodynamics and renal excretory function in IDDM was shown by other authors [41, 441. Although further studies are needed to elucidate this issue, it has to be pointed out that some of these latter investigations were performed in hyperglycemic IDDM patients [41] , in whom, as suggested by Trevisan et al [42] , the natriuretic action of ANP could have been enhanced by hyperglycemia.
With regard to the mechanisms explaining the blunted systemic and renal response to ANP in IDDM, it is interesting that other pathologic states characterized by chronic sodium retention and ECV expansion, such as congestive heart failure [37] and experimental nephrosis [45] , have been reported to have higher circulating levels and attenuated responses to ANP administration. The mechanisms underlying the abnormal renal response to ANP in IDDM are open to speculation. Among the possible hypotheses, an altered sensitivity of ANP receptors can be considered as a consequence of a decreased receptor number and/or affinity, secondary to down-regulation by elevated plasma ANP concentration. This hypothesis, however, appears unlikely, since it has been reported that rats with experimental nephrosis, in which ANP plasma concentrations are also chronically elevated, have normal ANP receptor affinity and density in renal inner and outer medulla [45] .
Alternatively, the possibility can be considered that insulin can blunt the effects of ANP at the kidney level, As a matter of fact ANP action is due to a stimulation of GFR [35] , to inhibition of Na/H antiport activity in the inner medullary collecting duct cells [46] , and to inhibition of Na/H antiport in proximal tubular brush border membrane [47] . This latter mechanism is not due to the binding of ANP with specific receptors, which are missing at this kidney level, but is likely to be mediated by ANP-induced dopamine inhibition of Na-H antiport [47] . Insulin increases sodium reabsorption by renal proximal [3, 22] and distal tubules [25, 28] , and generally increases NaH antiport activity [48] .
The present study, however, provides convincing indirect evidence that the resistance to ANP action in IDDM is, to some extent, related to insulin-induced sodium retention via a chronic stimulation of ANP cardiac release by the expansion of ECV, which in turn down-regulates the hormone receptor density. The treatment with the angiotensin converting enzyme inhibitor, Cilazapril, was associated with a significant increase of sodium excretion rate in the first weeks of drug administration and with a decrease in the ECV at the end of the treatment. The overall loss of sodium pool magnitude during antihypertensive treatment was 679 mmol. This figure is roughly comparable to that calculated on the basis of the decrease in ECV (-4 liters) assuming a sodium concentration of 145 m, such as 580 mM. The difference could be accounted for by slight changes in sodium intake after the dismissal from the ward. It is interesting to highlight that we observed similar results using diuretic therapy (data not shown), which decreases sodium pool by completely different mechanisms from ACE inhibitors. Moreover, a significant inverse correlation was found between plasma ANP baseline concentration and ECV. Interestingly, this decrease in baseline levels of ANP, was also accompanied by higher natriuretic response to hormone infusion, although the circulating levels of insulin did not change. These findings suggest that Cilazapril inhibits the chronic stimulation of ANP release, mainly by ameliorating sodium homeostasis, and that this effect is associated with an improved hormone action in vivo.
Whatever the mechanism accounting for the refractoriness to the renal and hemoconcentrating effects of ANP infusion in patients with IDDM, where endogenous plasma hormone release is chronically stimulated by insulin-induced expansion of ECY, a decreased responsiveness to, rather than an impaired cardiac release of ANP, plays a major role in the pathogenesis of sodium and water retention in IDDM and can further deteriorate the untoward effects of insulin therapy on sodium homeostasis.
